Literature DB >> 6321013

Prevalence of delta antigen/antibody in B-viral-associated hepatocellular carcinoma.

S Govindarajan, F J Hevia, R L Peters.   

Abstract

Sera from 39 patients with B-viral associated hepatocellular carcinoma were studied for the presence of delta antibody using solid-phase blocking radioimmunoassay. Only one patient (2.5%) had circulating delta antibody in the serum, and stainable delta antigen in the nuclei of the nontumor liver. A similar study of the sera of 57 patients with chronic B-viral disease without hepatocellular carcinoma revealed 18 patients (31.5%) with delta antibody. This significant difference (P less than 0.001) in the prevalence of delta antibody among these two groups is probably related to the epidemiologic background, reflected as a racial difference.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321013     DOI: 10.1002/1097-0142(19840415)53:8<1692::aid-cncr2820530812>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Anti-delta antibody in primary hepatocellular carcinoma patients in the Gizan area of Saudi Arabia.

Authors:  S J Ashraf; S C Arya; C M Parande; R Sahay; A R Ageel
Journal:  Infection       Date:  1986 Sep-Oct       Impact factor: 3.553

2.  Hepatitis delta infections.

Authors:  K G Nicholson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-05-11

3.  Serological markers of hepatitis B virus and hepatitis D virus infections in Greek adults with primary hepatocellular carcinoma.

Authors:  N C Tassopoulos; G Theodoropoulos; M H Sjogren; R Engle; R H Purcell
Journal:  Infection       Date:  1989 Jan-Feb       Impact factor: 3.553

Review 4.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

Review 5.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.